Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2011-10-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypoxia is a the major trigger of vascular endothelial growth factor (VEGF), which is in turn the most important factor for the development of macular edema. It is a major issue to improve the oxygen situation and the blood flow of the retina and there are just a few not satisfactory procedures available to overcome this problem. However, vitrectomy would be an adequate therapy for many of these diseases, and it would be an appreciated side effect of the treatment in almost every case.
To investigate the influence of oxygenation and blood flow of the retina on clinical outcomes after a successfully 23 gauge vitrectomy in eyes with epiretinal membrane, persistent macular edema following diabetic retinopathy or retinal vein occlusion.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V
NCT00563121
Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy
NCT00407108
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
NCT00612261
Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial
NCT00379223
Cryotherapy of Sclerotomy Sites for Prevention of Late Postvitrectomy Diabetic Hemorrhage
NCT00370409
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Epiretinal membrane
No interventions assigned to this group
diabetic macular edema
No interventions assigned to this group
vein occlusion
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ophthalmoscopic evidence of epiretinal membrane scheduled for vitrectomy and membrane peeling.
* persistent diabetic macular edema
* written informed consent
* female patients of childbearing potential must have a negative urine pregnancy test.
Exclusion Criteria
* symptoms of a clinically relevant illness in the 3 weeks before the first study day
* any ocular condition that in the opinion of the investigator would be a contraindication for the surgical procedure
* history of glaucoma, aphakie or presence of anterior chamber intraocular lens, choroidal neovascularisation, significant cataract, any ocular infection, - history of pars plana vitrectomy.
* contraindication to pupil dilation.
* need for silicon oil or gas after the surgery
* advanced diabetic retinopathy with vitreoretinal tear and/or bleeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stefan Sacu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefan Sacu
Ass Prof Priv Doz Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Opthalmology/Clinical Pharmacology
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VE-Oxygen-28062010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.